Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort

Background IBDs are chronic destructive disorders that negatively affect the functional status of patients. Recently, the Inflammatory Bowel Disease Disability Index (IBD-DI) was developed according to standard WHO processes. The aims of the current study were to validate the IBD-DI in an independent patient cohort, to develop an index-specific scoring system and to describe the disability status of a well-defined population-based cohort of French patients with IBD. Methods From February 2012 to March 2014, the IBD-DI questionnaire was administered to a random sample of adult patients with an established diagnosis of IBD issued from a French population-based registry. The IBD-DI consists of 28 items that evaluate the four domains of body functions, activity participation, body structures and environmental factors. Validation included item reduction and data structure, construct validity, internal consistency, interobserver and intraobserver reliability evaluations. Results 150 patients with Crohn's disease (CD) and 50 patients with UC completed the IBD-DI validation phase. The intraclass correlation coefficient for interobserver reliability was 0.91 and 0.54 for intraobserver reliability. Cronbach's α of internal consistency was 0.86. IBD-DI scores varied from 0 to 100 with a mean of 35.3 (Q1=19.6; Q3=51.8). IBD-DI scores were highly correlated with Inflammatory Bowel Disease Questionnaire (−0.82; p<0.001) and SF-36 (–0.61; p<0.05) scores. Female gender (p<0.001), clinical disease activity (p<0.0001) and disease duration (p=0.02) were associated with higher IBD-DI scores. Conclusions The IBD-DI has been validated for use in clinical trials and epidemiological studies. The IBD-DI showed high internal consistency, interobserver reliability and construct validity, and a moderate intraobserver reliability. It comprises 14 questions and ranges from 0 to 100. The mean IBD-DI score was 35.3 and was associated with gender, clinical disease activity and disease duration. Further research is needed to confirm the structural validity and to assess the responsiveness of IBD-DI. Trial registration number 2011-A00877-34

[1]  R. Hernaez,et al.  Reliability and agreement studies: a guide for clinical investigators , 2015, Gut.

[2]  B. Sands,et al.  Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. , 2015, Gastroenterology.

[3]  Lao Juan,et al.  Development and Validation of a Scale for Measuring Instructors' Attitudes toward Concept-Based or Reform-Oriented Teaching of Introductory Statistics in the Health and Behavioral Sciences , 2010, 1007.3219.

[4]  C. Zerbini,et al.  Patient and Physician Expectations of Add‐On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes , 2014, Arthritis care & research.

[5]  R. Leong,et al.  Prospective validation study of the International Classification of Functioning, Disability and Health score in Crohn's disease and ulcerative colitis. , 2014, Journal of Crohn's & colitis.

[6]  L. Peyrin-Biroulet,et al.  Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  L. Kappos,et al.  Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  M. Kamm,et al.  Development and validation of a patient‐reported disability measurement tool for patients with inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.

[9]  L. Dauchet,et al.  Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[10]  R. Escorpizo,et al.  International Classification of Functioning, Disability and Health Core Set construction in systemic sclerosis and other rheumatic diseases: a EUSTAR initiative. , 2012, Rheumatology.

[11]  M. Lunt,et al.  Influence of age and sex on functional outcome over time in a cohort of patients with recent‐onset inflammatory polyarthritis: Results from the Norfolk arthritis register , 2011, Arthritis care & research.

[12]  F. Casellas,et al.  Development and validation of the Crohn's disease perceived work disability questionnaire , 2011, Inflammatory bowel diseases.

[13]  P. Auquier,et al.  Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: Assessment using the MusiQoL and SF-36 questionnaires , 2011, Multiple sclerosis.

[14]  F. Kohler,et al.  Feasibility of using a checklist based on the international classification of functioning, disability and health as an outcome measure in individuals following lower limb amputation , 2011, Prosthetics and orthotics international.

[15]  Caroline B. Terwee,et al.  Measurement in Medicine: A Practical Guide , 2011 .

[16]  A. Cieza,et al.  Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health , 2011, Gut.

[17]  V. Chouraki,et al.  The changing pattern of Crohn’s disease incidence in northern France: a continuing increase in the 10‐ to 19‐year‐old age bracket (1988–2007) , 2011, Alimentary pharmacology & therapeutics.

[18]  Caroline B. Terwee,et al.  Measurement in Medicine: Index , 2011 .

[19]  L. Peyrin-Biroulet.  What Is the Patient’s Perspective: How Important Are Patient-Reported Outcomes, Quality of Life and Disability? , 2010, Digestive Diseases.

[20]  C. Terwee,et al.  The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. , 2010, Journal of clinical epidemiology.

[21]  A. Cieza,et al.  Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health , 2010, Inflammatory bowel diseases.

[22]  J. Sellin.  Disability in IBD: the devil is in the details. , 2010, Inflammatory bowel diseases.

[23]  J. Ellenberg,et al.  Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.

[24]  R. Osborne,et al.  The SF36 Version 2: critical analyses of population weights, scoring algorithms and population norms , 2007, Quality of Life Research.

[25]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[26]  W. Best.  Predicting the Crohn's disease activity index from the harvey‐bradshaw index , 2006, Inflammatory bowel diseases.

[27]  É. Lerebours,et al.  Opposite evolution in incidence of Crohn’s disease and ulcerative colitis in Northern France (1988–1999) , 2004, Gut.

[28]  B. Giraudeau,et al.  Planning a reproducibility study: how many subjects and how many replicates per subject for an expected width of the 95 per cent confidence interval of the intraclass correlation coefficient , 2001, Statistics in medicine.

[29]  C. Bombardier,et al.  Guidelines for the process of cross-cultural adaptation of self-report measures. , 2000, Spine.

[30]  F. Casellas,et al.  Impact of Inflammatory Bowel Disease on Health-Related Quality of Life , 2000, Digestive Diseases.

[31]  J. Bartelsman,et al.  Inflammatory Bowel Disease Questionnaire: cross-cultural adaptation and further validation , 1995, European journal of gastroenterology & hepatology.

[32]  J. Colombel,et al.  Incidence of inflammatory bowel disease in northern France (1988-1990). , 1994, Gut.

[33]  P. Thompson,et al.  A comparison of disability measured by the Stanford Health Assessment Questionnaire disability scales (HAQ) in male and female rheumatoid outpatients. , 1991, British journal of rheumatology.

[34]  J. Noseworthy,et al.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial , 1990, Neurology.

[35]  J. Horn.  A rationale and test for the number of factors in factor analysis , 1965, Psychometrika.